Pathology Department, Biomedical Research Institute A Coruña (INIBIC), University Hospital Complex A Coruña, 15006 A Coruña, Spain.
Santiago de Compostela Health Research Institute (IDIS), University Hospital Complex Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Int J Mol Sci. 2024 Sep 3;25(17):9567. doi: 10.3390/ijms25179567.
The early detection of tumors is one of the key factors in increasing overall survival in cancer patients. A wide range of cancers still do not have a system of early diagnosis; therefore, the development of new non-invasive tools in this line is essential. Accordingly, the objective of our work was to develop a non-invasive screening method for the early detection of various carcinomas in plasma using a panel that combines two markers using RT-qPCR. A retrospective case-control study was conducted to develop a cancer screening test based on the detection of stromal and epithelial biomarkers (COL1A2 and KRT19) in plasma. The expression of biomarkers was evaluated using multiplex quantitative PCR applied to 47 cases with non-metastatic tumors and 13 control participants. For both biomarkers, a cut-off value was stablished using Youden's J index through ROC curve analysis and areas under the curve (AUC) were calculated. The plasma mRNA expression level of both biomarkers was significantly higher in diseased versus healthy patients. Moreover, ROC curve analysis showed an AUC value of 0.897 for the combined model. This model also resulted in a cutoff value of 0.664, as well as a sensitivity of 83% and a specificity of 84.6%. These results suggest that the plasma expression levels of COL1A2 and KRT19 could a have potential role in detecting various types of cancer at the early stages. The combined analysis of both stromal and epithelial biomarkers would provide a non-invasive screening method that would allow us to differentiate patients with an active neoplastic process.
肿瘤的早期检测是提高癌症患者总体生存率的关键因素之一。许多癌症仍然没有早期诊断系统;因此,在这方面开发新的非侵入性工具至关重要。因此,我们的工作目标是开发一种使用 RT-qPCR 组合两种标志物的非侵入性筛选方法,用于早期检测血浆中的各种癌。进行了一项回顾性病例对照研究,以基于检测基质和上皮生物标志物(COL1A2 和 KRT19)在血浆中开发癌症筛查测试。使用应用于 47 例非转移性肿瘤和 13 例对照参与者的多重定量 PCR 评估生物标志物的表达。对于这两个生物标志物,通过 ROC 曲线分析使用 Youden 的 J 指数确定了截断值,并计算了曲线下面积(AUC)。与健康患者相比,患病患者的两种生物标志物的血浆 mRNA 表达水平均显着更高。此外,ROC 曲线分析显示组合模型的 AUC 值为 0.897。该模型还产生了 0.664 的截断值,以及 83%的灵敏度和 84.6%的特异性。这些结果表明,COL1A2 和 KRT19 的血浆表达水平可能在早期检测各种类型的癌症方面具有潜在作用。基质和上皮生物标志物的联合分析将提供一种非侵入性筛选方法,使我们能够区分具有活跃肿瘤过程的患者。